Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)

Bibliografske podrobnosti
Main Authors:	Adams, R, Wilson, R, Seymour, M, Meade, A, Madi, A, Cassidy, J, Fisher, D, Kenny, S, Kaplan, R, Maughan, T
Format:	Journal article
Izdano:	2009

Podobne knjige/članki

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS
od: Adams, R, et al.
Izdano: (2010)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
od: Madi, A, et al.
Izdano: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
od: Madi, A, et al.
Izdano: (2012)

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL
od: Madi, A, et al.
Izdano: (2010)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
od: Adams, R, et al.
Izdano: (2011)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
od: Adams, R, et al.
Izdano: (2009)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
od: Maughan, T, et al.
Izdano: (2009)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
od: Maughan, T, et al.
Izdano: (2010)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
od: Maughan, T, et al.
Izdano: (2011)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS
od: Adams, R, et al.
Izdano: (2009)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
od: Wasan, H, et al.
Izdano: (2011)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
od: Maughan, T, et al.
Izdano: (2010)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
od: Adams, R, et al.
Izdano: (2008)

Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
od: Seymour, M, et al.
Izdano: (2007)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
od: Wood, G, et al.
Izdano: (2017)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
od: Seymour, M, et al.
Izdano: (2007)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
od: Maughan, T, et al.
Izdano: (2010)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
od: Seymour, M, et al.
Izdano: (2011)

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.
od: Maughan, T, et al.
Izdano: (2003)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
od: Taieb, J, et al.
Izdano: (2012)

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
od: Madi, A, et al.
Izdano: (2018)

A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RAS STATUS
od: Vale, C, et al.
Izdano: (2009)

Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis
od: Diana Groza, et al.
Izdano: (2018-05-01)

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
od: Smith, C, et al.
Izdano: (2013)

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
od: Iveson, T, et al.
Izdano: (2018)

Role for nucleotide-excision repair gene variants in oxaliplatin-induced peripheral neuropathy
od: West, H, et al.
Izdano: (2018)

Sarcoidosis Associated with Oxaliplatin-Based Chemotherapy for Colorectal Cancer
od: Ji Hoon Choi, et al.
Izdano: (2014-01-01)

A pilot study of the use of Oxaliplatin in metastatic colorectal cancer at Velindre
od: Mitra, S, et al.
Izdano: (2001)

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
od: Mukherjee, S, et al.
Izdano: (2017)

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.
od: Vale, C, et al.
Izdano: (2012)

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
od: Vale, C, et al.
Izdano: (2012)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
od: J. M. Short, et al.
Izdano: (2023-09-01)

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.
od: Harrison, G, et al.
Izdano: (2000)

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.
od: Maughan, T, et al.
Izdano: (2002)

PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA
od: A. V. Pavlysh, et al.
Izdano: (2015-03-01)

Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
od: Vale, C, et al.
Izdano: (2009)

Superiority and non-inferiority: Two sides of the same coin?
od: Dunn, D, et al.
Izdano: (2018)

Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer
od: Gray, V, et al.
Izdano: (2019)

Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial.
od: Harry Tagbor, et al.
Izdano: (2010-12-01)

Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer
od: Violaine Randrian, et al.
Izdano: (2022-06-01)